RankAlpha logo
Back to Rankings

EW

Edwards LifesciencesB
NYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
View Chart

AI scenario view

RankAlpha Sentiment AI
B+
Bull case
25%
Probability
Target price
$110.00
Analysis reference price unavailable
Analysis 2026-02-12 · RankAlpha Sentiment AI
Most likely
B
Base case
55%
Probability
Target price
$95.00
Analysis reference price unavailable
Analysis 2026-02-12 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$76.80
Analysis reference price unavailable
Analysis 2026-02-12 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-02-12
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+76.3
Score

AI commentary

Market tone is cautiously constructive: consensus analyst targets sit above the current anchor, indicating base-case upside while mixed results have prompted some downward revisions [#SERP-2][#SERP-3]. Newsflow and analyst action remain the primary near-term drivers, with sentiment hinging on quarterly performance and trial/regulatory updates [#SERP-6].

RankAlpha Sentiment AI - 2026-02-12
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-05-13catalystNext quarterly earnings reportHigh impact

Upcoming quarterly results will test revenue growth and margin trajectory after mixed Q4 commentary; EPS/margin beats or misses likely to drive near-term re-rating [#SERP-3].

2026-06-30eventAnalyst target revisions and coverage updatesHigh impact

Ongoing analyst revisions (downgrades/target cuts or upgrades) following results and guidance will shift 12-month consensus targets; monitor published updates [#SERP-2][#SERP-4].

2027-02-12catalystPivotal device/clinical readout or major regulatory milestoneHigh impact

Material trial readouts or regulatory approvals for transcatheter or surgical valve franchises could drive durable upside or downside; timing is longer-term and binary [#SERP-1].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-02-12 • Updated nightlySource: Internal modelMethodology